To: Instock who wrote (142 ) 5/8/1998 12:22:00 PM From: Platter Read Replies (1) | Respond to
BRADLEY PHARMACEUTICALS INC (BPRX) 2 23/32 +15/32. The big companies depend on Wall Street analysts to tell their stories for them. But, if you are a $15 million market-cap company, with $15 million per/year in sales, there are not likely to be many, if any, analysts knocking on your door. So what is company of this size, with no voice on Wall Street, left to do when they think that the fundamentals are changing for the better? Issue a press release. When Pfizer's impotence drug Viagra began to fly out the apothecary like aspirin, analysts up-and-down Wall Street were upgrading the stock and raising earnings estimates. But now that the bedroom unemployment rate is forecast to decline to its lowest level in decades, there must be other companies in the economy that will benefit from this surge in new activity. Bradley Pharmaceuticals thinks it will be one of those companies. BPRX is drawing a fairly straight-forward conclusion from all this Viagra hype: It takes two to tango, but with Viagra only one partner gets a new pair of dancing shoes. Not quite making sense of the analogy. Well here are the facts according to BPRX: Bradley Pharmaceuticals foresees male Viagra patients increased sexual drive significantly affecting female usage of Lubrin Vaginal Lubricant inserts. It is estimated in excess of 20 million post-menopausal women currently suffer from vaginal dryness. Already, the company is reporting increased sales for Lubrin since the introduction of Viagra and says that it expects sales to increase more with increased sexual activity among middle-aged Viagra users and their partners. Since we reported this story yesterday on "In Play," BPRX shares have climbed 26%....from Briefing.com
